HOME >> BIOLOGY >> NEWS
Other highlights in the September 21 JNCI

Study Reports Elevated Risk of Second Cancers for Testicular Cancer Survivors

Men who survive testicular cancer have an increased risk of developing a second cancer for at least 35 years after diagnosis, according to the largest study to date of testicular cancer survivors.

Testicular cancer largely affects young men, and the 10-year survival rate of the disease is as high as 95%, so most men survive testicular cancer. However, these men have an increased risk of developing second cancers, mostly because of the late side effects of treatment. These cancers are a leading cause of death for testicular cancer patients.

To determine the risks of second cancers among long-term survivors of testicular cancer, Lois B. Travis, M.D., of the National Cancer Institute, and colleagues examined data from 40,576 1-year survivors of testicular cancer from population-based tumor registries in Europe and North America. A total of 2,285 second solid cancers were reported among these men anywhere from 1 year to more than 35 years after their testicular cancer diagnosis.

Ten-year survivors who had been diagnosed with testicular cancer at age 35 had a risk of developing a second cancer that was nearly twice that of the general population, and this risk remained elevated for 35 years. Risks were higher for patients diagnosed with testicular cancer at younger ages and lower for patients diagnosed at older ages. Cancers of the bladder, colon, lung, pancreas, and stomach accounted for 60% of the total excess risk. The authors conclude that testicular cancer survivors are at increased risk of solid tumors for at least 35 years after treatment and that young patients may face high levels of risk as they get older.

Contact: National Cancer Institute Press Office, 301-496-6641, NCIPressOfficers@mail.nih.gov

Hormone Replacement Therapy Associated With Increases in Mammographic Breast Den
'"/>

Contact: Sarah L. Zielinski
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
20-Sep-2005


Page: 1 2 3 4 5

Related biology news :

1. Other highlights in the Aug. 7 JNCI
2. Other highlights in the July 24 JNCI
3. Other highlights from the July 10 JNCI
4. Other highlights in JNCI, June 26
5. Other highlights in JNCI, June 12
6. Other highlights from the June 6 JNCI
7. Other highlights in the May 16 JNCI
8. Other highlights from the April 18 Journal of the National Cancer Institute
9. Other highlights from the March 21 JNCI
10. Other highlights in the March 7 JNCI
11. Other highlights in the Feb. 21 JNCI

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Other highlights the September JNCI

(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/12/2015)... Aug. 12, 2015  New research unveiled at ... Android phones to steal users, fingerprints. Information released ... of fingerprint scanners on mobile devices, making the ... secure biometrics on mobile devices, HYPR Corp. recently ... convenient authentication systems with strong cryptographic security. More ...
(Date:8/11/2015)... -- Today, ZUK announced its Android smartphone Z1, featuring ... revenues in 2015 that relate to sales of FPC1155 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... smartphone manufacturer in China and we ... 155 for Z1 , ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
(Date:8/27/2015)... GlassesOff (OTCBB: GLSO), a visual neuroscience technology company ... system, announced today a partnership with eight-time All-Star, ... to develop a new mobile app designed for professional and ... performance. Vision is the inception of every move ... or blocking a pass. The critical impact vision speed has ...
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet Biologics, a leader in ... is to open in Manhattan, Kansas in early October, 2015. The location of ... research and development through collaboration with researchers from Kansas State University’s College of ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic company ... has received a $1.5M Phase II SBIR grant ... further develop its therapeutic agent to reduce arteriovenous ... in end stage renal disease (ESRD) patients undergoing ... Institute of Diabetes and Digestive and Kidney Diseases ...
(Date:8/26/2015)... 26, 2015 Despite recent ... the optimism in biotech,s forecast is the recent ... sciences advancements.  Active biotechnology & healthcare companies with ... (OTCQB: PBIO), Sequenom, Inc. (NASDAQ: SQNM ), ... Pharmaceutical Corp. (NASDAQ: RPTP ) and EnteroMedics ...
Breaking Biology Technology:Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7
Cached News: